The Outcomes of ICSI Cycles With and Without Letrozole

EMBRYO IMPLANTATION Clinical Trial

Official title:

The Outcomes of ICSI Cycles With and Without Letrozole and Its Correlation With Mid-luteal Endometrial αvβ3 Integrin and Leukemia Inhibitory Factor

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04159649
• Other study ID #: ZU-IRB
• Status: Recruiting
• Phase: Phase 4
• Start date: December 1, 2019
• Est. completion date: December 30, 2020

Study information

• Verified date: November 2019
• Source: Mansoura University
• Contact: Eman ElGindy, MD, PhD
• Phone: 01227491143
• Email: eman_elgindy2013[@]hotmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A variety of genes working together with ovarian hormones conducts and precisely control the process of endometrial receptivity and implantation.

Leukemia inhibitory factor and αvβ3 integrin are two markers of implantation with at most importance. Reports have emphasized that these important biomarkers have a great role during the process of embryonic implantation.

αvβ3 integrin is one of the adhesion molecules which has a critical role in blastocyst apposition and attachment. Many studies have demonstrated that abnormal expression of αvβ3 integrin is associated with poor reproductive outcomes. Other studies haven't found a strong relation between αvβ3 integrin expression and reproductive outcomes Letrozole is an aromatase inhibitor which has been used in controlled ovarian stimulation especially in women with PCOS . Data suggests that letrozole addition to gonadotropins during ovarian stimulation protocols improve the response of the ovaries to FSH in low responders and increase the number of preovulatory follicles without adversely affect the outcomes.

Letrozole is used as an adjuvant therapy in ovarian stimulation protocols. So this study aims to evaluate whether the use of letrozole in combination with gonadotropins and GnRH antagonist is superior to gonadotropins and antagonist alone in women undergoing ICSI treatment.

Furthermore, both αvβ3 integrin and leukemia inhibitory factor are important markers of endometrial receptivity and implantation. Therefore, this study aims to assess the correlation between mid-luteal gene expression of both αvβ3 integrin and leukemia inhibitory factor and the clinical outcomes of antagonist cycles with or without letrozole.

Description:

Embryo implantation depends on quality of the embryo, endometrial receptivity and embryo/endometrial interaction. It is estimated that two third of implantation failure is a result of defects in endometrial receptivity. A variety of genes working together with ovarian hormones conducts and precisely control the process of endometrial receptivity and implantation.

Leukemia inhibitory factor and αvβ3 integrin are two markers of implantation with at most importance. Reports have emphasized that these important bio-markers have a great role during the process of embryonic implantation . Both are expressed in the epithelial cells during the mid-secretory phase of the menstrual cycle in healthy fertile women and their absence is associated with infertility and recurrent pregnancy loss .

Leukemia inhibitory factor is a class of cytokines which plays a key role in the process of implantation in both human and animals . Studies suggest that absence of leukemia inhibitory factor in the endometrium has a negative impact on embryo implantation .

αvβ3 integrin is one of the adhesion molecules which has a critical role in blastocyst apposition and attachment. Many studies have demonstrated that abnormal expression of αvβ3 integrin is associated with poor reproductive outcomes . Other studies haven't found a strong relation between αvβ3 integrin expression and reproductive outcomes.

Letrozole is an aromatase inhibitor which has been used in controlled ovarian stimulation especially in women with PCOS . Data suggests that letrozole addition to gonadotropins during ovarian stimulation protocols improve the response of the ovaries to FSH in low responders and increase the number of preovulatory follicles without adversely affect the outcomes.

The study by Miller and his colleagues suggested that letrozole might improve αvβ3 integrin expression with possible increase in pregnancy and implantation rate. They suggested that, this drug may be a useful adjunct therapy during IVF protocols .

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 224
• Est. completion date: December 30, 2020
• Est. primary completion date: December 30, 2020
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 40 Years

Eligibility

Inclusion Criteria:

Women aged from 18 - 40 years old.

• Regular menstrual cycle (25-35).

• Women undergoing ICSI cycle

Exclusion Criteria:

Women younger than 18 or older than 40 years old.

• Women who had unilateral oophorectomy.

• Women who had uterine abnormality or pathology.

• Women who will not meet the inclusion criteria.

• Women who will refuse to participate in in the study.

• ICSI cycles with fresh or frozen TESE samples.

Related Conditions & MeSH terms

• EMBRYO IMPLANTATION

Intervention

Drug:
• Letrozole 2.5Mg Tablet
Gonadotropins with or letrozol in fixed Gn RH antagonist IVF protocol
• Gonadotropins
Gonadotropins without letrozol in fixed Gn RH antagonist IVF protocol

Procedure:
• endometrial sample in the pretreatment cycle
All participant will be exposed to mid luteal endometrial sample in the pretreatment cycle. couples will be asked to use condom in the pretreatment cycle.

Locations

Country	Name	City	State
Egypt	Mansoura University	Mansoura

Sponsors (2)

Lead Sponsor	Collaborator
Mansoura University	Zagazig University

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	ongoing pregnancy rate.	Number of pregnant women with viable fetus at 12 weeks gestation per woman randomized	12 weeks
Secondary	endometrial thickness at day of HCG administration	Thickness of endometrium	9-12 days from first day of menstruation when at least three growing follicle reaches above 18 mm
Secondary	estrogen and progesterone levels during day of HCG,	estrogen and progesterone serum levels	9-12 days from first day of menstruation when at least three growing follicle reaches above 18 mm
Secondary	Rate of implantation	Number of gestational sac recognized by ultrasound in uterus 3 weeks after embryo transfer	21 days after embryo transfer
Secondary	Rate of clinical pregnancy	Number of gestational sacs with evident fetal pulsations per woman randomized	5 weeks after embryo transfer
Secondary	miscarriage rate	Number of miscarriages per woman with positive pregnancy tests	20 weeks
Secondary	multiple pregnancy rate	Number of multiple pregnancies per pregnant women with evident fetal pulsations	12 weeks
Secondary	Correlation between mid-luteal gene expression of both avß3 integrin and leukemia inhibitory factor and the clinical outcomes of antagonist cycles with or without letrozole.	Correlation between mid-luteal gene expression of both avß3 integrin and leukemia inhibitory factor and the clinical outcomes of antagonist cycles with or without letrozole.	8 weeks